Peut-on modifier les facteurs de risque liés aux gènes modificateurs ?
Certaines modifications du mode de vie peuvent réduire le risque, mais pas tous les facteurs sont modifiables.
Modification du mode de vieRisque génétique
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gènes modificateurs : Questions médicales les plus fréquentes",
"headline": "Gènes modificateurs : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gènes modificateurs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-30",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gènes modificateurs"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Gènes",
"url": "https://questionsmedicales.fr/mesh/D005796",
"about": {
"@type": "MedicalCondition",
"name": "Gènes",
"code": {
"@type": "MedicalCode",
"code": "D005796",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gènes modificateurs",
"alternateName": "Genes, Modifier",
"code": {
"@type": "MedicalCode",
"code": "D060045",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Harriet Corvol",
"url": "https://questionsmedicales.fr/author/Harriet%20Corvol",
"affiliation": {
"@type": "Organization",
"name": "Sorbonne Université, Inserm U938, Centre de Recherche Saint-Antoine (CRSA), 75012 Paris, France."
}
},
{
"@type": "Person",
"name": "Yuanjian Chen",
"url": "https://questionsmedicales.fr/author/Yuanjian%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Fuyi Xu",
"url": "https://questionsmedicales.fr/author/Fuyi%20Xu",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Robert W Williams",
"url": "https://questionsmedicales.fr/author/Robert%20W%20Williams",
"affiliation": {
"@type": "Organization",
"name": "Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
},
{
"@type": "Person",
"name": "Syamal K Bhattacharya",
"url": "https://questionsmedicales.fr/author/Syamal%20K%20Bhattacharya",
"affiliation": {
"@type": "Organization",
"name": "Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Immunophenotyping of pulmonary sarcomatoid carcinoma.",
"datePublished": "2022-10-20",
"url": "https://questionsmedicales.fr/article/36341325",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.976739"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immune infiltration and immunophenotyping in atrial fibrillation.",
"datePublished": "2023-01-04",
"url": "https://questionsmedicales.fr/article/36602538",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18632/aging.204470"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immunophenotypic characterization of acute leukemias in Bahia, Brazil.",
"datePublished": "2023-01-06",
"url": "https://questionsmedicales.fr/article/36629681",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31744/einstein_journal/2023AO0117"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Immunophenotypic Profile of Healthy Human Bone Marrow.",
"datePublished": "2023-06-04",
"url": "https://questionsmedicales.fr/article/37481314",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cll.2023.04.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Describing IgA Myeloma: An Immunophenotypic and Molecular Approach.",
"datePublished": "2022-08-01",
"url": "https://questionsmedicales.fr/article/35882000",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gènes modificateurs",
"item": "https://questionsmedicales.fr/mesh/D060045"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gènes modificateurs - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gènes modificateurs",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gènes modificateurs",
"description": "Comment identifier les gènes modificateurs ?\nQuels tests sont utilisés pour les gènes modificateurs ?\nLes gènes modificateurs sont-ils testés en routine ?\nPeut-on détecter les gènes modificateurs par imagerie ?\nQuel rôle jouent les gènes modificateurs dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunophenotyping#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gènes modificateurs",
"description": "Les gènes modificateurs affectent-ils les symptômes ?\nQuels symptômes sont liés aux gènes modificateurs ?\nLes gènes modificateurs causent-ils des symptômes ?\nPeut-on prédire les symptômes avec des gènes modificateurs ?\nLes gènes modificateurs sont-ils liés à des symptômes spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunophenotyping#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gènes modificateurs",
"description": "Peut-on prévenir les effets des gènes modificateurs ?\nY a-t-il des mesures préventives spécifiques ?\nLes gènes modificateurs nécessitent-ils une prévention ciblée ?\nComment la recherche aide-t-elle à la prévention ?\nLes gènes modificateurs influencent-ils le mode de vie préventif ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunophenotyping#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gènes modificateurs",
"description": "Les traitements ciblent-ils les gènes modificateurs ?\nComment les gènes modificateurs influencent-ils le traitement ?\nY a-t-il des traitements spécifiques pour les gènes modificateurs ?\nLes gènes modificateurs affectent-ils l'efficacité des médicaments ?\nPeut-on modifier les gènes modificateurs par traitement ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunophenotyping#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gènes modificateurs",
"description": "Quels types de complications sont liés aux gènes modificateurs ?\nLes gènes modificateurs augmentent-ils les complications ?\nComment gérer les complications liées aux gènes modificateurs ?\nLes complications sont-elles prévisibles avec des gènes modificateurs ?\nLes gènes modificateurs sont-ils impliqués dans des complications spécifiques ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunophenotyping#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gènes modificateurs",
"description": "Quels sont les facteurs de risque liés aux gènes modificateurs ?\nLes gènes modificateurs augmentent-ils le risque de maladies ?\nComment évaluer les facteurs de risque génétiques ?\nLes facteurs environnementaux influencent-ils les gènes modificateurs ?\nPeut-on modifier les facteurs de risque liés aux gènes modificateurs ?",
"url": "https://questionsmedicales.fr/mesh/D060045?mesh_terms=Immunophenotyping#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les gènes modificateurs ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse génétique et les études d'association sont utilisées pour identifier ces gènes."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les gènes modificateurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de séquençage et les SNP (polymorphismes nucléotidiques) sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils testés en routine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, leur test n'est pas systématique et dépend des maladies spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les gènes modificateurs par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'imagerie ne permet pas de détecter les gènes modificateurs, seuls les tests génétiques le peuvent."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les gènes modificateurs dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils aident à comprendre la variabilité des maladies et à affiner le diagnostic."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs affectent-ils les symptômes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer la gravité et la présentation des symptômes d'une maladie."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux gènes modificateurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon la maladie, mais incluent souvent des manifestations cliniques variées."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs causent-ils des symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils modifient l'expression des symptômes causés par d'autres gènes."
}
},
{
"@type": "Question",
"name": "Peut-on prédire les symptômes avec des gènes modificateurs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Partiellement, car ils peuvent influencer la sévérité mais pas toujours la présence des symptômes."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils liés à des symptômes spécifiques ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes modificateurs sont associés à des symptômes spécifiques dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets des gènes modificateurs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est complexe, mais une surveillance et un dépistage précoce peuvent aider."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des conseils génétiques et des tests peuvent être proposés aux familles à risque."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs nécessitent-ils une prévention ciblée ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la prévention peut être ciblée en fonction des gènes modificateurs identifiés."
}
},
{
"@type": "Question",
"name": "Comment la recherche aide-t-elle à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La recherche sur les gènes modificateurs aide à identifier des stratégies préventives efficaces."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs influencent-ils le mode de vie préventif ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent guider les recommandations de mode de vie pour réduire les risques."
}
},
{
"@type": "Question",
"name": "Les traitements ciblent-ils les gènes modificateurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains traitements peuvent être adaptés en fonction des gènes modificateurs identifiés."
}
},
{
"@type": "Question",
"name": "Comment les gènes modificateurs influencent-ils le traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent déterminer la réponse au traitement et la nécessité d'une approche personnalisée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les gènes modificateurs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il n'existe pas de traitements spécifiques, mais des approches personnalisées peuvent être envisagées."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs affectent-ils l'efficacité des médicaments ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer l'efficacité et les effets secondaires des médicaments."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les gènes modificateurs par traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur la thérapie génique, mais ce n'est pas encore courant."
}
},
{
"@type": "Question",
"name": "Quels types de complications sont liés aux gènes modificateurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications varient selon la maladie, incluant des formes plus graves ou résistantes."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs augmentent-ils les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de complications dans certaines conditions génétiques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées aux gènes modificateurs ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une gestion proactive et personnalisée est essentielle pour minimiser les complications."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles avec des gènes modificateurs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Partiellement, car certains gènes modificateurs peuvent indiquer un risque accru de complications."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs sont-ils impliqués dans des complications spécifiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes modificateurs sont associés à des complications spécifiques dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque liés aux gènes modificateurs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux et des variations génétiques spécifiques."
}
},
{
"@type": "Question",
"name": "Les gènes modificateurs augmentent-ils le risque de maladies ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent augmenter le risque de développer certaines maladies génétiques."
}
},
{
"@type": "Question",
"name": "Comment évaluer les facteurs de risque génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation se fait par des tests génétiques et des conseils génétiques appropriés."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux influencent-ils les gènes modificateurs ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'environnement peut interagir avec les gènes modificateurs et influencer le risque."
}
},
{
"@type": "Question",
"name": "Peut-on modifier les facteurs de risque liés aux gènes modificateurs ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines modifications du mode de vie peuvent réduire le risque, mais pas tous les facteurs sont modifiables."
}
}
]
}
]
}
Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN, United States of America. Electronic address: llu@uthsc.edu.
Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America. Electronic address: yasun@uthsc.edu.
Previous studies have suggested that patients with pulmonary sarcomatoid carcinoma (PSC)may benefit from immune checkpoint inhibitors (ICIs); however, relevant data are lacking. This study aimed to es...
A retrospective analysis of pathologically confirmed PSC cases from two centers was performed from January 2009 to May 2021. According to the infiltration of CD8+ T cells in different spatial regions,...
A total of 32 patients with PSC were included in the final analysis. Of these patients, 65.6% (21/32), 15.6% (5/32), and 18.8% (6/32) were classified as immune-inflamed, immune-excluded, and immune-de...
Patients with PSC are characterized by immune-inflamed type and type I (PD-L1+/CD8+, adaptive immune resistance), explaining the intrinsic reasons for their high response rate to immunotherapy....
Atrial fibrillation (AF) is a relatively common arrhythmia in clinical practice. Although significant progress has been achieved in the treatment of AF and its associated complications, research on AF...
To characterize the immunophenotypic profile of acute leukemias in the population of the state of Bahia, Brazil....
This is a descriptive, retrospective study. From 2014 to 2018, 796 new cases of acute leukemia were evaluated. The data were obtained from analysis of reports and records of tests performed by flow cy...
Most cases were diagnosed as acute myeloid leukemia and 42.7% as acute lymphoblastic leukemia. Significant differences were found in expression of markers in acute leukemias when age groups were compa...
Significant differences were found as to several antigens when comparing adults and children, and these findings may contribute to future studies correlating the phenotypic profile to genetic characte...
Flow cytometry enables multiparametric characterization of hematopoietic cell immunophenotype. Deviations from normal immunophenotypic patterns comprise a cardinal feature of many hematopoietic neopla...
Plasma cell myeloma (PCM) is defined as a clonal disease of terminally differentiated plasma cells that secrete immunoglobulin. The biologic underpinnings of IgA-type multiple myeloma's (IgAMM) aggres...
ASD reconstructions are a major, sterile traumatic insult, likely causing perturbations to the immune systems. The immune response to surgery is associated with outcomes. The purpose of this study was...
Consecutive patients undergoing ASD surgery were approached and enrolled. Peripheral blood was drawn before incision, 4 h after, and 24 h after incision. Blood was stabilized and comprehensive flow cy...
Thirteen patients were enrolled; 11(85%) F, 65.4 years (± 7.5), surgical duration 418 ± 83 min, EBL 1928 ± 1253 mL. Hierarchical clustering and PCA found consistent time from incision-dependent change...
Despite surgery and patient heterogeneity, we identified an immune signature associated with the sterile trauma of ASD surgery. Circulating leukocyte populations change in composition and signaling pr...
We aimed to provide an autophagy-related signature to seek immunophenotyping biomarkers in osteoarthritis (OA)....
Microarray expression profiling of OA subchondral bone samples and screening of an autophagy database for autophagy-related differentially expressed genes (au-DEGs) between OA and normal samples were ...
We screened 754 au-DEGs between OA and control samples, and co-expression networks were constructed using au-DEGs. Three OA-related autophagy hub genes (HSPA5, HSP90AA1, and ITPKB) were identified. Ba...
Three autophagy-related markers of OA were identified using bioinformatics methods, and these markers may be useful for the autophagy-related immunophenotyping of OA. The present data may facilitate t...
Prompt diagnosis of acute promyelocytic leukemia (APL) is critical for patient care. In this study, we aimed to characterize the immunophenotype of APL and explore immunophenotypic difference between ...
Eighty-five cases were collected, including 47 APL, 26 NPM1-mutated acute myeloid leukemia (AML) and 12 KMT2A-rearranged AML with an APL-like immunophenotype. Immunophenotypes were analyzed using flow...
APL showed four distinct patterns (designated a-d) based on CD45/SSC plots. Blasts in patterns a-c showed high side scatter, whereas blasts in pattern d had low side scatter and were located in the tr...
APL and its immunophenotypic mimics share some immunophenotypic similarities but can be distinguished by CD2, CD13, CD34, CD64, and MPO....
Acute myeloid leukemia (AML) with RAM immunophenotype is a distinct subtype of AML, as described by the Children's Oncology Group (COG), with characteristic morphological and immunophenotypic properti...
Seven cases with the characteristic RAM immunophenotype were identified in this retrospective analysis of newly diagnosed pediatric AML cases from January 2019 to December 2021. Herein, we have critic...
Of 302 cases of pediatric AML (age <18 years), seven cases (2.3%) with the distinct RAM phenotype were observed, with age ranging from 9 months to 5 years. Two patients were misdiagnosed earlier as sm...
AML with RAM immunophenotype, a distinct form of pediatric AML with a poor prognosis, may pose a diagnostic challenge if presented as a soft tissue mass. A comprehensive immunophenotypic evaluation, i...
Tγδ large granular lymphocyte leukemia (Tγδ LGLL) is a rare lymphoproliferative disease, scantily described in literature. A deep-analysis, in an initial cohort of 9 Tγδ LGLL compared to 23 healthy co...